Vidac pharma Holding Plc Press Releases - EIN Presswire - Press Release Distribution Service

Published on December 15, 2025 - 15:15 GMT

Vidac Pharma Holdings Plc Announces Commencement of Trading on Xetra

Trading on Frankfurt Deutsche Börse’s Xetra platform enhances Vidac Pharma’s visibility and access to European investors Vidac Pharma Holdings Plc. (XETR:T9G; ISIN: GB00BM9XQ619; WKN: A3DTUQ) LONDON, UNITED KINGDOM, December 15, 2025 /⁨EINPresswire.com⁩/ …

Distribution channels: Banking, Finance & Investment Industry, Chemical Industry ...

Published on December 11, 2025 - 06:00 GMT

Vidac Pharma Holdings Plc Initiates Phase 2B Trial for Targeted Treatment of Highly Proliferative Actinic Keratosis

Vidac Pharma advances a Phase 2B trial with a novel approach to treating highly proliferative Actinic Keratosis Vidac Pharma Holdings Plc. (XDUS:T9G; ISIN: GB00BM9XQ619; WKN: A3DTUQ) LONDON, UNITED KINGDOM, December 11, 2025 /⁨EINPresswire.com⁩/ -- Vidac …

Distribution channels: Banking, Finance & Investment Industry, Business & Economy ...

Published on December 2, 2025 - 10:17 GMT

Vidac Pharma Holdings Plc. Marks Major Milestone with Düsseldorf Stock Exchange Listing and Completed Public Offering

Company begins trading and completes public offering of 35,000 shares at EUR 0.54; milestone strengthens Vidac’s European market presence and growth strategy. Vidac pharma Holding Plc (XDUS:SYM: T9G; ISIN: GB00BM9XQ619; WKN: A3DTUQ) LONDON, UNITED …

Distribution channels: Banking, Finance & Investment Industry, Chemical Industry ...

Published on November 28, 2025 - 14:21 GMT

Vidac Pharma Holding PLC Approved for Inclusion on Düsseldorf Stock Exchange Open and Primary Markets

Public offering set for 1 December 2025 as Vidac Pharma Holding PLC secures Düsseldorf Stock Exchange approval for Open and Primary Market inclusion. Vidac Pharma Holding plc. (XSTU:ISIN: GB00BM9XQ619; WKN: A3DTUQ) LONDON, UNITED KINGDOM, November 28, …

Distribution channels: Banking, Finance & Investment Industry, Companies ...

Published on November 27, 2025 - 06:00 GMT

Vidac Pharma Invited to Present at the 17th International Investment Forum (IIF) on December 3rd, 2025

Vidac Pharma to present at the 17th International Investment Forum on Dec 3, 2025, with CEO Dr. Max Herzberg highlighting clinical progress and strategy Vidac Pharma Plc (Xstu:T9G; ISIN: GB00BM9XQ619; WKN: A3DTUQ) LONDON, UNITED KINGDOM, November 27, …

Distribution channels: Banking, Finance & Investment Industry, Business & Economy ...

Published on November 24, 2025 - 17:09 GMT

VIDAC PHARMA Upcoming Inclusion in Open Market of Düsseldorf Stock Exchange, Primary Market Segment, and Public Offering

Vidac Pharma Holding Plc (XSTU:ISIN: GB00BM9XQ619; WKN: A3DTUQ) LONDON, UNITED KINGDOM, November 24, 2025 /⁨EINPresswire.com⁩/ -- THE INFORMATION CONTAINED IN THIS DOCUMENT IS NOT FOR PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN, WITHIN OR FROM …

Distribution channels: Banking, Finance & Investment Industry, Business & Economy ...

Published on November 21, 2025 - 08:57 GMT

Vidac Pharma Receives Renewed “Buy” Rating from Sphene Capital Following German Authorization for New Phase 2 AK Trial

Vidac wins renewed “Buy” rating as Phase 2 AK trial gets green light in Germany -analysts see major upside ahead. Vidac Pharma Holding Plc. (XSTU:T9G; ISIN: GB00BM9XQ619; WKN: A3DTUQ) LONDON, UNITED KINGDOM, November 21, 2025 /⁨EINPresswire.com⁩/ -- …

Distribution channels: Business & Economy, Chemical Industry ...

Published on November 4, 2025 - 07:14 GMT

Vidac Pharma is proud to announce Clinical Trial Approval in Germany following CTIS update

The trial will test Vidac’s first-in-class therapy reversing the Warburg effect to treat high-risk actinic keratosis lesions Vidac pharma Holding Plc (XSTU:SYM: T9G; ISIN: GB00BM9XQ619; WKN: A3DTUQ) LONDON, UNITED KINGDOM, November 4, 2025 /⁨EINPresswire …

Distribution channels: Business & Economy, Chemical Industry ...

Published on October 23, 2025 - 08:57 GMT

Vidac Pharma to Present Possible Cooperation with Johnson & Johnson at Basel Launch’s ‘Beyond the Needle’ Event

Vidac Pharma (XSTU:Hamburg and Stuttgart: T9G; ISIN: GB00BM9XQ619; WKN: A3DTUQ) LONDON, UNITED KINGDOM, October 23, 2025 /⁨EINPresswire.com⁩/ -- Vidac Pharma Holdings Plc. a clinical-stage oncology company pioneering first-in-class therapies targeting the …

Distribution channels: Banking, Finance & Investment Industry, Chemical Industry ...

Published on October 21, 2025 - 05:44 GMT

VIDAC PHARMA HOLDING PLC Plans Inclusion of Its Shares in the Open Market of the Düsseldorf Stock Exchange

The planned inclusion aims to enhance share tradability and facilitate future access to XETRA trading. Vidac Pharma PLC (XSTU:T9G; ISIN: GB00BM9XQ619; WKN: A3DTUQ) LONDON, UNITED KINGDOM, October 21, 2025 /⁨EINPresswire.com⁩/ -- VIDAC PHARMA HOLDING PLC …

Distribution channels: Banking, Finance & Investment Industry, Business & Economy ...

Published on September 30, 2025 - 20:33 GMT

Vidac Pharma Secures U.S. Patent Protection for Mitochondria-Targeted Cancer Therapy

USPTO Grants Notice of Allowance for Patent Claims Covering Vidacs Innovative HK2-Detaching Compounds Designed to Restore Mitochondrial Function in Cancer Cells Vidac Pharma Holding Plc. (XSTU:T9G; ISIN: GB00BM9XQ619; WKN: A3DTUQ) LONDON, UNITED KINGDOM, …

Distribution channels: Chemical Industry, Companies ...

Published on September 30, 2025 - 05:00 GMT

Vidac Pharma Announces Broad U.S. Patent Claim Allowance for HK2-Detaching Compounds in Cancer Treatment

Notice of Allowance Covers Compounds, Compositions, and Methods for Treating HK2-Expressing Cancers Vidac Pharma Holding Plc (XSTU:T9G; ISIN: GB00BM9XQ619; WKN: A3DTUQ) LONDON, UNITED KINGDOM, September 30, 2025 /⁨EINPresswire.com⁩/ -- Vidac Pharma …

Distribution channels: Chemical Industry, Companies ...

Published on September 15, 2025 - 05:00 GMT

Vidac Pharma Submits Clinical Study Application to EMA for Advanced Actinic Keratosis Lesions

Comprehensive dossier underscores rigorous scientific, clinical, and CMC preparation, with key support from CRO partners Vidac pharma Holding Plc (XSTU:SYM: T9G; ISIN: GB00BM9XQ619; WKN: A3DTUQ) LONDON, UNITED KINGDOM, September 15, 2025 /⁨EINPresswire. …

Distribution channels: Banking, Finance & Investment Industry, Chemical Industry ...

Published on September 2, 2025 - 05:00 GMT

Sphene Equity Research Update Reaffirms “Buy” Rating on Vidac Pharma

Continued analyst endorsement underscores confidence in shareholder value and growth potential Vidac pharma Holding Plc (XSTU:SYM: T9G; ISIN: GB00BM9XQ619; WKN: A3DTUQ) LONDON, UNITED KINGDOM, September 2, 2025 /⁨EINPresswire.com⁩/ -- Vidac Pharma …

Distribution channels: Chemical Industry, Companies ...

Published on July 9, 2025 - 05:00 GMT

Vidac Pharma Holding Strengthens Leadership and Prepares for Accelerated Growth

Appointment of new CTO and planned stock exchange listing mark strategic steps toward the company’s next growth phase Vidac pharma Holding Plc (XSTU:SYM: T9G; ISIN: GB00BM9XQ619; WKN: A3DTUQ) LONDON, UNITED KINGDOM, July 9, 2025 /⁨EINPresswire.com⁩/ -- …

Distribution channels: Chemical Industry, Companies ...

Published on June 25, 2025 - 05:00 GMT

Vidac Pharma Receives 'Buy' Rating and Increased Valuation from Sphene Capital, Underscoring Strong Growth Prospects

Sphene Capital Cites Strong Clinical Pipeline and Unique Approach to Tumor Microenvironment Disruption Vidac Pharma Plc (XSTU:T9G; ISIN: GB00BM9XQ619; WKN: A3DTUQ) LONDON, UNITED KINGDOM, June 25, 2025 /⁨EINPresswire.com⁩/ -- Vidac Pharma Plc, a clinical …

Distribution channels: Banking, Finance & Investment Industry, Business & Economy ...

Published on June 17, 2025 - 05:00 GMT

European Commission Selects Vidac Pharma’s Tuvatexib™ Project for STEP Seal under EIC Accelerator

Vidac Pharma’s Tuvatexib™ project earns STEP Seal under Horizon Europe, recognizing its innovation in treating precancerous skin lesions. Vidac Pharma PLC (XSTU:T9G; ISIN: GB00BM9XQ619; WKN: A3DTUQ) LONDON, UNITED KINGDOM, June 17, 2025 /⁨EINPresswire. …

Distribution channels: Business & Economy, Chemical Industry ...

Published on June 10, 2025 - 05:00 GMT

Vidac Pharma Announces Publication of New Peer-Reviewed Study Highlighting Breakthrough Anti-Cancer Mechanism of VDA1275

The article explores the potential of VDA1275 both as a standalone therapy and in synergistic combination with traditional chemotherapy Vidac pharma Holding Plc (XSTU:SYM: T9G; ISIN: GB00BM9XQ619; WKN: A3DTUQ) LONDON, UNITED KINGDOM, June 10, 2025 /⁨ …

Distribution channels: Business & Economy, Chemical Industry ...

Published on May 28, 2025 - 05:00 GMT

Vidac Pharma Reports Exceptional Pharmacokinetics of Almavid™ Drug Candidate in Real-World Clinical study

Revolutionary cancer treatment demonstrates potential for Almavid™ Drug Candidate application in solid tumors. Vidac pharma Holding Plc (XSTU:SYM: T9G; ISIN: GB00BM9XQ619; WKN: A3DTUQ) LONDON, UNITED KINGDOM, May 28, 2025 /⁨EINPresswire.com⁩/ -- Vidac …

Distribution channels: Business & Economy, Chemical Industry ...

Published on March 24, 2025 - 06:00 GMT

Vidac Pharma Launches “TME++” Pediatric Brain Tumor Research Consortium

Vidac Pharma has announced the formation of “TME++,” a groundbreaking research consortium dedicated to advancing treatments for pediatric brain tumors. Vidac pharma Holding Plc (XSTU:SYM: T9G; ISIN: GB00BM9XQ619; WKN: A3DTUQ) UNITED KINGDOM, March 24, …

Distribution channels: Chemical Industry, Companies ...